GlassScriptPhysician profile
Daniel K Kimple
NPI 1699030551
$17,079.77
in general payments reported to CMS, 2019-2025
61 companies · $4,021 in 2025
The $4,021 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $769 · 2021: $1,910 · 2022: $2,648 · 2023: $3,377 · 2024: $3,297 · 2025: $4,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,366.16 |
| Travel and Lodging | $328.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,209.68 | 2020-2025 | |
| Livanova USA, INC. | $1,190.07 | 2020-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,056.43 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Harmony Biosciences LLC | $749.08 | 2021-2025 | Wakix |
| Amgen INC. | $734.92 | 2019-2022 | |
| Celgene Corporation | $699.88 | 2021-2025 | Zeposia |
| Sk Life Science, INC. | $693.92 | 2020-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $602.00 | 2020-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $567.58 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Acadia Pharmaceuticals INC | $538.05 | 2020-2025 | Nuplazid |
| Emd Serono, INC. | $494.78 | 2019-2025 | Mavenclad |
| Pfizer INC. | $455.88 | 2023-2025 | |
| Biogen, INC. | $429.00 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Teva Pharmaceuticals USA, INC. | $380.08 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Eisai INC. | $375.22 | 2020-2025 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $359.66 | 2021-2025 | Valtoco |
| Genzyme Corporation | $329.10 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $324.06 | 2021-2023 | |
| Genentech USA, INC. | $323.87 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Lundbeck LLC | $304.58 | 2023-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $286.03 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $273.63 | 2023-2024 | Aptiom |
| Novartis Pharmaceuticals Corporation | $272.69 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $267.66 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $199.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.46 | 2025 | Hyqvia |
| Alnylam Pharmaceuticals INC. | $189.50 | 2022 | |
| Jazz Pharmaceuticals INC. | $183.69 | 2020-2025 | Xywav |
| Allergan, INC. | $178.40 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $147.96 | 2021-2022 | |
| Acorda Therapeutics, INC | $147.06 | 2019-2023 | Inbrija, Ampyra |
| Adamas Pharmaceuticals, INC. | $132.85 | 2020-2021 | |
| Abbott Laboratories | $128.48 | 2019-2025 | Infinity |
| Boston Scientific Corporation | $121.62 | 2021-2024 | Watchman Access System, Wavewriter Alpha Prime 16 |
| Amneal Pharmaceuticals LLC | $111.37 | 2019-2025 | Rytary, Crexont |
| Avion Pharmaceuticals | $102.96 | 2022 | |
| Ge Healthcare | $98.54 | 2021-2024 | |
| Medtronic USA, INC. | $95.96 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $95.50 | 2025 | Xeomin, Inbrija |
| Catalyst Pharmaceuticals, INC. | $92.67 | 2021-2024 | Firdapse |
| Ipsen Biopharmaceuticals, INC | $91.42 | 2024-2025 | Dysport |
| Upsher-Smith Laboratories LLC | $91.19 | 2020-2022 | |
| Kyowa Kirin, INC. | $87.48 | 2021-2024 | Nourianz |
| Medtronic, INC. | $66.61 | 2021-2022 | |
| Tanabe Pharma America, INC. | $66.51 | 2023-2025 | Radicava |
| Cycle Pharmaceuticals INC | $65.96 | 2024-2025 | Tascenso Odt, Bafiertam |
| Impel Pharmaceuticals INC. | $63.30 | 2022-2023 | Trudhesa |
| Averitas Pharma INC. | $60.11 | 2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $46.35 | 2023-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $44.09 | 2019 | |
| Grifols USA, LLC | $43.78 | 2025 | Gamunex-C |
| Csl Behring | $32.20 | 2024 | Hizentra |
| Vanda Pharmaceuticals INC. | $31.80 | 2025 | Ponvory |
| Horizon Therapeutics Plc | $25.78 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.35 | 2021 | |
| Janssen Biotech, INC. | $22.91 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.23 | 2022 | |
| Mdd US Operations, LLC | $16.19 | 2022 | |
| Greenwich Biosciences, INC. | $15.97 | 2020 | |
| Electromed, INC. | $12.71 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kimple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.